On September 2, 2020 Sutro Biopharma, Inc. (NASDAQ: STRO) reported that Wendel Naumann, M.D., gynecologic oncologist at Levine Cancer Institute, along with Sutro executives, Bill Newell, Chief Executive Officer, Dr. Arturo Molina, Chief Medical Officer, Dr. Trevor Hallam, Chief Scientific Officer, and Edward Albini, Chief Financial Officer, will host a conference call on Wednesday, Sept. 9, 2020, at 5:30 p.m. EDT to discuss updated data from the company’s ongoing Phase I dose escalation study of anti-Folate Receptor alpha (FRα) antibody-drug conjugate (ADC), STRO-002, in ovarian and endometrial cancer, with a data cut-off date of Aug. 31, 2020 (Press release, Sutro Biopharma, SEP 2, 2020, View Source [SID1234564355]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Additionally, the company announced a presentation at the upcoming 2020 xDigital Annual Global Meeting of the International Gynecologic Cancer Society (IGCS), being held Sept. 10-13, 2020. The virtual presentation will include Phase 1 dose escalation clinical data for STRO-002, with an efficacy data cut-off date of August 3, 2020. The abstract announcing the digital poster presentation, with a data cut-off date of July 10, 2020, may be found on the IGCS conference site at View Source on page 97 of the "Digital Poster" PDF and on Sutro’s website; the IGCS poster will be available following market close on September 9, 2020.
Conference Call Information:
To access the conference call and live audio webcast on Wednesday, Sept. 9, at 5:30 p.m. EDT, please dial (877) 407-8974 (domestic) or (201) 389-0894 (international).
The conference call will be webcast via the Investors page on the Company’s website at ir.sutrobio.com. Approximately two hours following the live event, a webcast replay of the conference call will be available through the Company Presentation page of the Investor section of the company’s website at www.sutrobio.com for approximately 30 days.
World ADC Conference
Three Sutro executives will also present at World ADC Digital 2020 being held Sept. 15-18, 2020. Dr. Hallam will present proof of concept data for a next generation dual conjugated combination immunostimulatory antibody drug conjugate (IADC). Dr. Molina will review the efficacy and safety data from the STRO-002 Phase 1 dose escalation study in ovarian cancer. Dr. Shabbir Anik, Chief Technical Operations Officer, will discuss commercialization of Sutro’s proprietary GMP cell-free protein synthesis platform XpressCF and its use in the GMP manufacture of antibody / protein drug conjugates with site-specific conjugation in its XpressCF+ system.
Presentations Details:
2020 IGCS xDigital Annual Global Meeting (Virtual Poster Presentation)
Phase 1 Dose-Escalation Study of STRO-002, an anti-Folate Receptor alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum-Resistant/Refractory Epithelial Ovarian Cancer (OC)
Presenter: Wendel Naumann, M.D.
Date/Time: Sept. 10-13, 2020
Abstract Number 138 IGCS20_1113
The virtual poster presentation will be also accessible through the Clinical/Scientific Presentation and Publication Highlights page of the News section of the company’s website at www.sutrobio.com on the day of the poster presentation.
World ADC Digital
Tumor-Targeted In Situ Immunization; Off-The Shelf & Systemically-Administered
Presenter: Dr. Trevor Hallam
Date/Time: Sept. 16, 2020, 4:00 p.m. EDT
Session Title: Uncovering the Wave of Next Generation Successful Conjugates
Treatment of Ovarian & Endometrial Cancer with the Novel Folate Receptor-α-targeting Antibody Drug Conjugate, STRO-002
Presenter: Dr. Arturo Molina
Date/Time: Sept. 17, 2020, 12:10 p.m. EDT
Session Title: Exploring ADCS in Phase I Clinical Development
A Look into the Future of Upstream Biologics Processing: Industrialization of Cell-Free Protein Synthesis
Presenter: Dr. Shabbir Anik
Date/Time: Sept. 16, 2020, 2:20 p.m. EDT
Session Title: Keeping Things Clean; Removing Impurities
The virtual presentations can be accessed by World ADC Digital attendees on the event page. Following the event, the slides will be accessible through the Clinical/Scientific Presentation and Publication Highlights page of the News section of the company’s website at www.sutrobio.com.